Taken together, these results suggest that where KRAS mutation is a biomarker of cetuximab response in colorectal cancer [45], in HNSCC, KRAS amplification may be a predictive marker of cetuximab resistance. The gene discussed is KRAS; the disease is head and neck squamous cell carcinoma.